Related Experiment Video

Updated: Mar 16, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

14.4K

Non-cytochrome P450-mediated bioactivation and its toxicological relevance

Jinping Gan1, Shuguang Ma2, Donglu Zhang2

  • 1a Pharmaceutical Candidate Optimization, Bristol-Myers Squibb , Princeton , NJ , USA.

Drug Metabolism Reviews
|August 18, 2016
PubMed

Insights

Drug bioactivation by non-cytochrome P450 (CYP) enzymes is crucial for understanding toxicity. This review highlights non-CYP enzyme roles in drug metabolism and adverse reactions, complementing existing CYP research.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Toxicology

Background:

  • Drug bioactivation is linked to toxicity, but mechanisms are often unclear.
  • Cytochrome P450 (CYP) enzymes are extensively studied for drug metabolism, overshadowing other enzymes.
  • Increasingly, new drugs utilize non-CYP enzymes for clearance, necessitating broader research.

Purpose of the Study:

  • To review non-CYP enzyme-mediated drug bioactivation pathways.
  • To complement existing literature focused on CYP-mediated bioactivation.
  • To provide examples of non-CYP bioactivation across different enzyme categories.

Main Methods:

  • Literature review focusing on non-CYP enzymes.
  • Categorization of non-CYP enzymes by function (oxidative, reductive, conjugative, hydrolytic).
  • Identification and presentation of representative examples for each category.

Main Results:

  • Non-CYP enzymes play a significant role in drug bioactivation.
  • Bioactivation by non-CYP enzymes can lead to toxicological outcomes.
  • Diverse non-CYP enzymes contribute to drug metabolism and potential adverse effects.

Conclusions:

  • Understanding non-CYP bioactivation is essential for drug safety and discovery.
  • Further research into non-CYP pathways will enhance prediction of drug toxicity.
  • This review provides a foundation for exploring non-CYP mediated adverse drug reactions.
Keywords:
Drug bioactivationconjugation reactionshydrolytic reactionsnon-CYP enzymesreductive reactions

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.3K
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.8K

Related Concept Videos

Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
78
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
5.5K
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
99
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
858
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
114
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
102